GSK583 is a potent and selective inhibitor of RIPK1 (receptor-interacting serine/threonine-protein kinase 1), primarily used in medical and pharmacological research. It is investigated for its potential to inhibit enzyme activities involved in necroptosis and inflammatory signaling pathways linked to inflammatory diseases, autoimmune disorders such as rheumatoid arthritis, and certain cancers where controlling cell growth and death is crucial. Its applications support the development of therapeutic strategies, with ongoing studies focusing on efficacy, safety, and potential clinical use.